SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending following the FDA approval of YARTEMLEA, making it the first and only approved therapy for the life-threatening transplant-associated thrombotic microangiopathy (TA-TMA). The community is celebrating this significant milestone, with discussions centered on the stock's perceived undervaluation, potential for a short squeeze, and heightened speculation around a buyout, especially given a prior licensing deal with Novo Nordisk.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is actively trending as its community intensely discusses a potential price reversal, with many holding onto hopes for substantial gains following recent market dips. While some vocal participants express frustration and question its long-term viability, others remain confident in its community-driven momentum and look for signs of a breakout, often contrasting its appeal with more infrastructure-focused crypto projects.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending following a recent clinical trial failure for its depression drug, a development released during a holiday period that drew community criticism for its timing. However, investor attention is quickly shifting to the company's robust pipeline, particularly upcoming data for its epilepsy, obesity, and oncology programs. Significant insider buying after a recent offering has also fueled renewed confidence, signaling a belief in future growth despite prior regulatory setbacks.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is a trending topic after reporting robust earnings, showcasing a critical milestone with its first positive adjusted EBITDA, coupled with increased revenue guidance that signals continued growth in AI-driven precision medicine. Despite these strong results and several analyst upgrades, the community is actively debating recent price volatility, with many expressing long-term conviction in the company's AI-driven healthcare platform while others point to "sell the news" dynamics and market manipulation.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax (DVAX) is trending due to the announcement that Sanofi will acquire the company for cash, a strategic move to bolster its adult immunization portfolio with DVAX's Hepatitis B vaccine, Heplisav-B, and a shingles candidate. The community is actively debating the acquisition price, with many long-term holders expressing disappointment and questioning if the company was undersold, while some speculate about potential counter-offers. This acquisition reflects ongoing consolidation in the biotech vaccine sector, integrating DVAX's assets into a larger pharmaceutical framework.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is trending as recent developments, including the closure of a public offering and significant technical validations like graduating Shell's GameChanger program and successful steam-cracking trials, energize investors. Community discussion highlights the company's de-risking milestones and vast market potential for its Hydrochemolytic technology, though skeptics continue to challenge its economic viability and commercial pathway.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

Spruce Biosciences is trending following the FDA's Breakthrough Therapy Designation for its rare neurological disease therapy and recent analyst upgrades. This major catalyst has sparked intense community debate, with bulls anticipating further upside due to its low float and potential acquisition interest, while others express concern over recent dilution from a private placement and its small target patient population.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is trending following the successful closing of an oversubscribed $400 million private placement and major operational milestones, including beginning drilling for its KRONOS microreactor prototype and securing significant R&D incentives. Community discussion highlights the strong institutional backing and positive progress, fueling optimism within the broader nuclear energy sector as demand for advanced microreactors surges, particularly to power AI data centers.

Exodus Movement, Inc. develops blockchain asset investors platform to secure, exchange and manage wealth inside one application. The company was founded by Daniel Castagnoli and Jon Paul Richardson in 2015 and is headquartered in Omaha, NE.

Exodus Movement Inc - Ordinary Shares - Class A

Exodus Movement is trending as a key player in the evolving digital asset landscape, celebrated for its self-custodial crypto wallet and pioneering tokenized stock on the Algorand blockchain. Community sentiment emphasizes its strong financial position, zero debt, and strategic expansion into Web3 and stablecoin payments, drawing comparisons to competitors for its decentralized approach. Analysts are upgrading ratings, fueling discussions around its significant undervaluation and growth potential amid a re-energized crypto market.

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

iRhythm Technologies Inc

iRhythm Technologies is trending due to compelling clinical trial results from its AMALFI study, demonstrating superior AFib detection and faster diagnoses with its Zio service, which has spurred renewed analyst optimism and a wave of positive rating adjustments. However, community discussion also highlights lingering regulatory scrutiny stemming from a prior FDA warning letter and competitive pressures from emerging cardiac monitoring technologies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


TedCruz

TedCruz